🇺🇸 FDA
Patent

US 8968736

Human antibodies to GFRα3 and methods of use thereof

granted A61KA61K2039/505A61K39/001103

Quick answer

US patent 8968736 (Human antibodies to GFRα3 and methods of use thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Mar 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2039/505, A61K39/001103, A61K39/39533, A61K39/39541